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Purpose. This study aimed to examine whether plasma levels of cathepsin S or its inhibitor, cystatin C, may serve as biomarkers for
COPD. Patients and Methods. We measured anthropometrics and performed pulmonary function tests and chest CT scans on 94
patients with COPD and 31 subjects with productive cough but no airflow obstruction (“at risk”; AR). In these subjects and in 52
healthy nonsmokers (NS) and 66 healthy smokers (HS) we measured plasma concentrations of cathepsin S and cystatin C using an
ELISA. Data were analyzed using simple and logistic regression and receiver operating characteristic analyses. Results. Cathepsin
S and cystatin C plasma levels were significantly higher in the COPD and AR groups than in the NS and HS groups (𝑝 < 0.01).
Among the COPD patients and AR subjects, plasma cathepsin S levels and cathepsin S/cystatin C ratios, but not cystatin C levels,
were negatively related to severe airflow limitation (% FEV1 predicted < 50%; 𝑝 = 0.005) and severe emphysema as assessed by low
attenuation area (LAA) score on chest CT scans (LAA ≥ 8.0; 𝑝 = 0.001). Conclusion. Plasma cathepsin S and cathepsin S/cystatin
C ratios may serve as potential biomarkers for COPD.
1. Introduction
COPD is characterized by narrowing of small airways and
lung parenchymal destruction, partly caused by chronic lung
inflammation including increased numbers of neutrophils,
macrophages, and CD8-positive T lymphocytes, oxidative
stress, and alveolar septal cell apoptosis [1–3]. Changes in the
% FEV1 predicted and clinical parameters such as exacerba-
tion rates are currently the most commonly used endpoints
for monitoring responses to therapies in COPD patients, but
these measures have limitations including a relatively long
duration of treatment and large number of subjects needed
for study in order to detect the changes in response to therapy.
Consequently, there is an urgent need to identify and validate
sensitive and reliable biomarkers for COPD in compartments
that are easy to sample, such as blood, to more quickly
assess the efficacy of novel therapies for COPD in clinical
trials. In particular, it will be crucially important to identify
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reliable biomarkers for early stage COPD, the stage at which
novel therapies might have the most impact on successfully
modifying the course of the disease and preserving lung
function.
Recent research has identified a number of poten-
tial molecules and pathways that could serve as potential
biomarkers and be targeted to develop novel therapies [4].
One such group of molecules is proteinases. There is com-
pelling evidence that an imbalance between the levels of
proteinases and their inhibitors in the lung contributes to
emphysema development. Proteinases such as neutrophil
elastase, matrix metalloproteases, and cysteine proteases
contribute to emphysema development and/or small airway
remodeling in COPD [5]. Another proteinase that has been
implicated in COPD pathogenesis is cathepsin S, a lysosomal
acidic proteinasewhich is highly expressed by cells implicated
in COPD pathogenesis including macrophages and dendritic
cells [6]. Cathepsin S level and activity in bronchoalveolar
lavage fluid from COPD patients are higher than those
from healthy volunteers [7]. Additionally, cathepsin S is a
potent elastin-degrading proteinase and participates in the
adaptive immune response [8]. Studies of murine models
of emphysema have implicated cathepsin S in promoting
lung inflammation and destruction [9]. The major inhibitor
of cathepsin S in extracellular fluids including plasma is
cystatin C which is expressed by alveolar macrophages, bron-
chioepithelial cells, and endothelial cells [10–12]. However,
this inhibitor has not been well studied in the context of
COPDandneither cathepsin S nor cystatinC levels have been
measured in plasma samples from human COPD patients.
We hypothesized that plasma concentrations of cathepsin
S and cystatin C would differ between COPD patients,
subjects with cough and sputum, and healthy smokers and
nonsmokers. To test this hypothesis, wemeasured the plasma
concentrations of cathepsin S and cystatin C and explored
the association between levels of these biomarkers with
degree of airflow obstruction and emphysema severity as
assessed by low attenuation areas on chest CT scans and
diffusing capacity of the lung for carbon monoxide (DLCO)
measurements.
2. Materials and Methods
2.1. Study Populations. This study subjects included 125
patients suggestive of COPD consecutively visiting the out-
patient clinic of Keio University Hospital from 2000 through
2003 and also included 118 healthy volunteers (age≥ 50 years).
All patients underwent pulmonary function tests (PFT) and
chest CT. The patients suspected of having clinically stable
COPD fulfilled the following criteria: (1) smoking history
of ≥ 10 pack-years or more; (2) age ≥ 40 years old; and
(3) having chronic respiratory symptoms including cough,
sputum, and dyspnea on exertion.The patients were excluded
if they were (1) having any pulmonary disease other than
COPD; (2) having serum creatinine level > 1.5mg/dL with
renal dysfunction; (3) having serious comorbidities including
unstable cardiovascular or cerebral diseases and treated
malignant tumors; (4) having self-reported asthma; and (5)
having an exacerbation for at least one month prior to
recruitment or being treated with oral corticosteroids. The
COPD patients (𝑛 = 94) were diagnosed based on airflow
obstruction as defined by a ratio of forced expiratory volume
in 1 second to forced vital capacity (FEV1/FVC) lower than
0.7 and an % FEV1 predicted value lower than the 95%
confidence interval for this population by PFT. One group of
31 subjects (at risk of developing COPD; AR) was defined as
having chronic respiratory symptoms (cough, sputum, and
dyspnea on exertion) but no airflow limitation as assessed
by PFT. Enrolled healthy volunteers were classified into two
groups by smoking history: 52 healthy nonsmokers (NS) and
66 healthy smokers (HS). This study was approved by the
Ethics Committee of Keio University Hospital and informed
consent was obtained from each subject.
2.2. Measurement of Concentrations of Cathepsin S and
Cystatin C. Plasma concentrations of total cathepsin S were
measured in duplicate using the enzyme-linked immunosor-
bent assay (ELISA) kit (R&D systems, Inc. Minneapolis,
MN, USA) after diluting the samples 1 : 100 using the diluent
supplied by the kit manufacturer. The lower detectable limit
of cathepsin S using these kits was 15.6 pg/mL. Plasma
concentrations of cystatin C were determined in duplicate
using a sandwich ELISA as previously described [13]. GT 13
was used as a mouse anti-cystatin C monoclonal antibody.
Plasma was also 100 times diluted with phosphate buffered
saline before the assay. The lower detectable limit of cystatin
C using this assay was 1.9 ng/mL.
2.3. Assessment of Clinical Parameters. Spirometry was per-
formed in all patients of the COPD and AR groups using
an electronic spirometer (MFR-8200; Nihon Kohden, Tokyo,
Japan). Regular treatment was not changed prior to spiromet-
ric testing. DLCO was estimated by 10 s breath holding inmost
patients of the COPD (𝑛 = 83) and AR (𝑛 = 20) groups
(𝑛 = 103) (Chestac-55V; Chest, Tokyo, Japan). Chest CT was
also performed in all patients of the COPD and AR groups
(Proseed, GE; Yokogawa Medical Systems, Tokyo, Japan).
To calculate emphysema severity, the entire lung was
divided into six zones (i.e., left and right zones in the upper,
middle, and lower lung fields). Low attenuation areas (LAA)
were visually scored in each zone on a scale from 0 to 4: 0, no
LAA; 1, 1–25%; 2, 26–50%; 3, 51–75%; 4, 76–100%. The total
(0–24) was assessed by three pulmonologists in a blinded
manner and the mean score was defined as the LAA score,
a quantitative indicator of emphysematous change [14, 15].
Diameters of main pulmonary artery and abdominal aorta at
the celiac artery were also measured on the chest CT images
[16].
2.4. Statistical Analysis. Data were expressed as the mean ±
SD. Plasma cathepsin S and cystatin C levels were compared
among the groups by analysis of variance and the Scheffe´ test.
Correlations between the plasma concentrations of cathepsin
S and cystatin C and clinical parameters were examined using
simple linear regression analysis. Independent associations
between the plasma concentrations of cathepsin S and cys-
tatin C and severe airflow limitation (% FEV1 predicted <
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Table 1: Study populations.
Healthy nonsmoker (NS) Healthy smoker (HS) COPD at risk (AR) COPD
𝑁 52 66 31 94
Male/female 50/2 65/1 27/4 89/5
Age 57.9 ± 2.3 56.6 ± 2.9 56.0 ± 5.9 68.3 ± 9.5∗∗∗
Current/Ex 0/0 40/26 14/17 37/57#
Pack-Years 0 37.1 ± 13.3 46.5 ± 27.7 66.0 ± 39.9†
BMI NA NA 22.4 ± 4.6 21.4 ± 3.1
Serum Cr NA NA 0.77 ± 0.16 0.82 ± 0.18
FEV1/FVC (%) NA NA 78.1 ± 4.2 49.2 ± 13.6
§
% FEV1 predicted NA NA 95.5 ± 8.5 55.3 ± 20.9
§
LAA NA NA 1.9 ± 3.1 7.3 ± 5.4§
HT (+/−) 0/52 0/66 5/26 17/77
ICS (+/−) 0/52 0/66 1/30 16/78
∗∗∗𝑝 < 0.0001 versus NS, HS, AR; #𝑝 < 0.05 versus HS; †𝑝 < 0.0001 versus HS, < 0.05 versus AR; §𝑝 < 0.0001 versus AR. COPD: chronic obstructive
pulmonary disease; BMI: body mass index; Cr: creatinine; FEV1/FVC (%): ratio of forced expiratory volume in 1 second to forced vital capacity; LAA: low
attenuation area; HT: hypertension; ICS: inhaled corticosteroid.
50%) or emphysematous change (LAA ≥ 8.0) were deter-
mined using logistic regression analysis. Logistic regression
analysis models were prepared to avoid the influence of
potential confounders, including age, sex, body mass index
(BMI), smoking status, serum creatinine levels, the presence
of hypertension, and treatment with inhaled corticosteroid
(ICS). Inclusion of variables was based on existing knowledge
of risk factors for COPD and on the factors related to
plasma cystatin C levels according to previous reports [17, 18].
We followed standard method to estimate sample size for
logistic regression analysis, with at least ten outcomes needed
for each included independent variable. Receiver operating
characteristic (ROC) analyses of plasma cathepsin S and
cystatin C levels and the cathepsin S/cystatin C ratio were
performed to examine the sensitivity and specificity of plasma
cathepsin S and cystatin C levels as biomarkers for COPD in
all participants. 𝑝 values < 0.05 were considered statistically
significant.
3. Results
3.1. Characteristics of Study Populations. As shown in Table 1,
the mean age in the COPD group was older than the other
three groups. The COPD group consisted of 14 Stage I, 40
Stage II, 29 Stage III, and 11 Stage IV patients defined by
the Global Initiative for Chronic Obstructive Lung Disease
(GOLD) 2014. The mean pack-year cigarette consumption in
the COPD group (mean ± SD 66.0 ± 39.9) was greater than
that in both theHS (37.1±13.3 𝑝 < 0.0001 versusCOPD) and
AR groups (46.5±27.7 𝑝 < 0.05 versus COPD). As expected,
both airflow obstruction and emphysema severity were more
severe in the COPD group than in the AR group but there
were no significant differences in BMI, serum creatinine
levels, frequencies of hypertension, or the use of ICS.
3.2. Plasma Concentrations of Cathepsin S and Cystatin C.
Themean value and the distribution of plasma concentrations
of cathepsin S, cystatin C, and cathepsin S/cystatin C ratios
among the four groups are shown in Figure 1. Plasma cathep-
sin S and cystatin C levels were significantly higher in the AR
and COPD groups than those in the NS and HS groups. The
cathepsin S/cystatin C ratio was also significantly higher in
the AR and COPD groups than in the NS and HS groups.
Cathepsin S levels in the HS group were higher than those
in the NS group. When we compared plasma cathepsin S and
cystatin C levels in GOLD stages I to IV COPD patients, we
found no significant differences in the levels of these proteins.
3.3. ROC Curves. The ROC curves are shown in Figure 2.
For plasma cathepsin S, the best threshold for discrimi-
nating between patients with versus without COPD was
≥ 16.2 ng/mL (80% sensitivity and 74% specificity). For
plasma cystatin C, a threshold of ≥ 2.1 𝜇g/mL had a 77%
sensitivity and 71% specificity, whereas for the plasma cathep-
sin S/cystatin C ratio a value of ≥ 6.4 × 10−3 had 78%
sensitivity and 64% specificity. Because the ROC curves for
plasma cathepsin S and cathepsin S/cystatin C ratios were
not symmetrical for sensitivity and specificity (Figure 2),
another threshold was determined to improve the sensitivity.
A cathepsin S level of≥ 12.1 ng/mL offered a sensitivity of 98%
with 62% specificity. When the plasma cathepsin S/cystatin
C ratio was ≥ 4.2 × 10−3, the sensitivity was 97% with 55%
specificity.
3.4. Regression Analyses. We then examined the associations
between plasma concentrations of cathepsin S or cystatin
C and FEV1/FVC or the LAA score in the COPD and AR
groups. Unexpectedly, both cathepsin S levels and cathepsin
S/cystatin C ratios correlated modestly but significantly with
FEV1/FVC and inversely with the LAA score, while cystatin
C levels did not correlate significantly with either of these
parameters (Figure 3).
Table 2 shows that cathepsin S correlated with % FEV1
predicted (𝑝 = 0.045) and % DLCO/𝑉𝐴 predicted (𝑝 =
0.046). Cystatin C levels correlated positively with age (𝑝 =
0.01), creatinine levels (𝑝 = 0.003), % DLCO predicted (𝑝 =
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Figure 1: Comparison of plasma levels of cathepsin S (a), cystatin C (b), and cathepsin S/cystatin C (c) between healthy nonsmokers (NS),
healthy smokers (HS), subjects at risk (AR), and COPD patients. Distribution of cathepsin S, cystatin C, and cathepsin S/cystatin C among
the groups is displayed along with mean ± SD values. Cut points were set at 16.2 ng/mL, 2.1 𝜇g/mL, and 6.4 × 10−3, respectively, and displayed
as dotted lines, based on the ROC analyses in Figure 2. Mean ± SD is presented. ∗∗ indicates 𝑝 < 0.01; ∗∗∗𝑝 < 0.001 versus NS, †𝑝 < 0.05,
††𝑝 < 0.01, and †††𝑝 < 0.001 versus HS.
0.01), diameter of the abdominal aorta (𝑝 = 0.005), and male
gender (𝑝 = 0.04). The cathepsin S/cystatin C ratios corre-
lated positively with % FEV1 predicted (𝑝 = 0.04), peak expi-
ratory flow rate (PEF) (𝑝 = 0.03), 𝑉50 (𝑝 = 0.04), % DLCO
predicted (𝑝 = 0.005), and % DLCO/𝑉𝐴 predicted (𝑝 = 0.01).
Tables 3 and 4 show that after normalizing for the
effects of age, BMI, pack-year, creatinine, gender, smoking
status, hypertension, and ICS, cathepsin S levels and age
were significantly correlated with the development of severe
airflow obstruction [𝑝 = 0.005, odds ratio (OR) = 0.32, and
𝑝 = 0.001, OR = 3.82, resp.]. Also, the cathepsin S/cystatin
C ratio (𝑝 = 0.02, OR = 0.87) and age (𝑝 = 0.001, OR
= 3.02) correlated to severe airway obstruction (Table 3).
Serum creatinine levels were also associated with severity of
airflow obstruction (Table 3). On the other hand, cathepsin S
(𝑝 = 0.001. OR = 0.28) and the cathepsin S/cystatin C ratio
(𝑝 = 0.002, OR = 0.82) were the strongest factors associated
inversely with the presence of severe emphysema (Table 4).
4. Discussion
This study shows for the first time that plasma cathepsin
S level and cathepsin S/cystatin C ratios are significantly
higher in COPD patients compared with healthy smokers
and healthy nonsmokers. This suggests that cathepsin S
participates in COPD pathogenesis in humans and that
plasma cathepsin S and cathepsin S/cystatin C ratios might
be potential biomarkers for COPD. It is also intriguing that
plasma cathepsin S and cathepsin S/cystatin C ratios tend
to be higher in patients with mild airflow limitation and
emphysema than those in patients with severe impairment.
Previous studies of animal models of emphysema have
implicated cathepsin S in promoting airspace enlargement
in mice [9, 19]. Cathepsin S is produced by activated
macrophages and dendritic cells. Cathepsin S is also pro-
duced by smooth muscle cells and endothelial cells in
human atherosclerotic lesions [20] and by adipose tissue [21].
Cathepsin S is a potent elastin-degrading proteinase which
retains substantial activity at neutral pH. Thus, cathepsin
S could promote airspace enlargement by degrading lung
elastin fibers. Cathepsin S is also expressed by antigen-
presenting cells such as macrophages and dendritic cells and
has crucial activities in processing antigens during MHC
class II-mediated immune processes [8, 22]. In this respect,
it is noteworthy that a recent hypothesis has suggested
that COPD is an autoimmune disease in which anti-elastin,
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Figure 2: ROC curves for cathepsin S (a), cystatin C (b), and cathepsin S/cystatin C (c). AUCwas 0.831, 0.806, and 0.710, respectively. Dotted
arrows indicate the best cutpoints for both sensitivity and specificity. Better sensitivities (98% and 97%, resp.) were obtained when the cut
points were set at cathepsin S ≥ 12.1 ng/mL and cathepsin S/cystatin C ≥ 4.2 × 10−3, indicated by the solid arrows in (a) and (c), and the
specificities were 62% and 55%, respectively.
epithelial, and endothelial cell antibodies promote disease
progression especially in patients with severe disease [23].
Studies of transgenic mice that overexpress IL-13 and IFN-
𝛾 in an inducible- and lung-specific manner develop lung
inflammation and emphysema due, in part, to increased lung
levels of cysteine proteinases including cathepsin S [9, 24].
Cathepsin S contributes to emphysema development in IFN-
𝛾 overexpressing transgenic mice by promoting epithelial cell
apoptosis [19]. Geraghty et al. have suggested a potential
contribution of IFN-𝛾-induced cathepsin S expression in
macrophages to the development of COPD [7]. However,
cathepsin S has not been well studied in humans. Plasma
cystatin C levels are increased by renal dysfunction [17] and
decreased in patients with aortic aneurysm [18] and COPD
patients often have comorbidities including cardiovascular
and renal disease, hypertension, and cachexia. Consistent
with the protease-antiprotease imbalance hypothesis for
COPD, we anticipated that COPD patients would have
increased plasma levels of cathepsin S along with reduced
plasma levels of its cognate inhibitor, cystatin C [5].
Surprisingly, our data showed that, in addition to plasma
cathepsin S levels, plasma levels of cystatin Cwere also higher
in COPD patients compared with the control groups. We
show that the differences in plasma levels of cathepsin S and
cathepsin S/cystatin C ratios between the COPD patients
and the control groups were not due to differences in BMI,
and prevalence of cardiovascular disease, as assessed by
measuring the diameters of the abdominal aorta and main
pulmonary artery, systemic hypertension, or renal dysfunc-
tion, as assessed by serum creatinine levels. We also show
that age and treatment with ICS, which can influence inflam-
matory cell activation, were not responsible for the observed
differences. The ROC analyses showed that the sensitivity of
plasma cathepsin S levels for the diagnosis of COPDwas very
6 Disease Markers
FE
V
1%
10
20
30
40
50
60
70
80
90
100
10 20 30 40 50 600
Cathepsin S (ng/mL)
r = 0.261
p < 0.01
(a)
NS
FE
V
1%
10
20
30
40
50
60
70
80
90
100
1 2 3 4 5 60 7
Cystatin C (𝜇g/mL)
(b)
FE
V
1%
10
20
30
40
50
60
70
80
90
100
5 10 15 20 250
cat S/cys C (/103)
r = 0.242
p < 0.01
(c)
10 20 30 40 50 600
Cathepsin S (ng/mL)
0
5
10
15
20
LA
A
r = −0.228
p < 0.05
(d)
NS
0
5
10
15
20
LA
A
1 2 3 4 5 6 70
Cystatin C (𝜇g/mL)
(e)
0
5
10
15
20
LA
A
5 10 15 20 250
cat S/cys C (/103)
r = −0.233
p < 0.01
(f)
Figure 3: The correlation of cathepsin S, cystatin C, or cathepsin S/cystatin C with either FEV1% or LAA score in the AR and COPD groups
(𝑛 = 125). Cathepsin S levels correlated modestly but significantly with FEV1/FVC (a) and inversely with the LAA score (d) (𝑟 = 0.261,
𝑝 < 0.01; 𝑟 = −0.228, 𝑝 < 0.05, resp.); also cathepsin S/cystatin C ratios correlated modestly but significantly with FEV1/FVC (c) and
inversely with the LAA score (f) (𝑟 = 0.242, 𝑝 < 0.01; 𝑟 = −0.223, 𝑝 < 0.01, resp.). In contrast, cystatin C levels did not correlate with either
FEV1/FVC (b) or LAA (e).
high (98%) when the threshold was set at ≥ 12.1 ng/mL. The
specificity improved from 62% to 80% if the threshold was
set at≥ 16.2 ng/mL but the sensitivity decreased to 74%.These
additional analyses suggest that plasma cathepsin S levelsmay
serve as a useful biomarker for COPD. Rokadia et al. also
reported that active smokers with COPD had significantly
higher plasma levels of cystatin C than healthy controls in
accordance with our results [25]. These observations might
imply that elevated plasma levels of cystatin C partly reflect
the defensive reaction against the effect of increased cathep-
sin S induced by smoking, still representing an imbalance
between the enhanced protease activity and inhibitory effects
of cystatin C in patients with COPD.
An unexpected result from our study was that, among
the COPD patients and AR subjects, plasma cathepsin S and
cathepsin S/cystatin C ratios were inversely correlated with
the extent of airflow obstruction and emphysema severity,
as assessed by LAA on CT scans, even after normalizing
for various confounding factors including age, gender, BMI,
renal function, smoking history, the presence of hyperten-
sion, and treatment with ICS. Thus, plasma cathepsin S
levels, but not cystatin C levels, were significantly increased
in patients with AR and with mild COPD when compared
with patients with severe airflow limitation and emphysema.
One possible explanation for the inverse correlation between
plasma cathepsin S and severity of disease among the COPD
patients is that cathepsin S is produced in lung tissue
including activated macrophages [6], and as COPD severity
increases there is progressive destruction of the alveolar walls
with loss of source of cathepsin S. Other cellular sources
of cathepsin S such as adipose tissue [21] could also be
altered quantitatively and qualitatively between the early and
late stages of COPD. Chronic airflow limitation assessed by
FEV1/FVC and % FEV1 predicted is positively associated
with BMI and malnutrition in a large number of COPD
patients [26], and plasma cathepsin S levels are reduced on
surgery-related weight loss, linking to reduction of cathepsin
S expression in subcutaneous adipose tissue mass [21]. Also,
proinflammatory stimuli that differ in expression levels in
the lung during the course of COPD differentially regulate
cathepsin S mRNA levels and protein secretion by cells [27].
Additionally, the main inhibitor of cathepsin S, cystatin C,
inhibits various cysteine proteinases including cathepsins L
and K, and lung production of these other cysteine pro-
teinases is also increased inCOPDpatients [10]. A prior study
reported that, unlike COPD patients, patients with asthma
have significantly reduced plasma cathepsin S levels when
compared to healthy control subjects [28].
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Table 2: Simple regression analysis.
Cathepsin S Cystatin C Cat S/Cys C (/103)
𝑅 𝑝 𝑅 𝑝 𝑅 𝑝
Age 0.033 0.72 0.226 0.01∗ −0.128 0.16
Pack-Year 0.099 0.27 0.096 0.29 −0.001 0.99
BMI 0.175 0.052 −0.042 0.65 0.132 0.14
Serum Cr 0.164 0.07 0.266 0.003∗∗ −0.093 0.30
% VC −0.0004 0.997 −0.054 0.55 0.076 0.40
FEV1/FVC 0.261 0.003
∗∗ −0.014 0.88 0.242 0.007∗∗
% FEV1 predicted 0.179 0.045
∗ −0.020 0.83 0.188 0.04∗
PEF 0.083 0.36 −0.1664 0.07 0.199 0.03∗
𝑉50 0.131 0.15 −0.110 0.23 0.187 0.04
∗
% DLCO predicted 0.089 0.37 −0.251 0.01
∗ 0.277 0.005∗∗
% DLCO/𝑉𝐴 0.197 0.046
∗ −0.120 0.23 0.244 0.01∗
LAA −0.228 0.01∗ 0.033 0.71 −0.233 0.009∗∗
mPA 0.112 0.24 0.139 0.14 −0.054 0.58
abAo 0.181 0.06 0.267 0.005∗∗ 0.045 0.64
Current/Ex (51/74) 24.8/22.8 0.17 2.78/2.65 0.44 9.77/9.42 0.65
HT (+/−) (22/103) 24.5/23.4 0.57 2.74/2.70 0.57 9.68/9.54 0.85
ICS (+/−) (17/108) 20.1/24.2 0.06 2.59/2.72 0.59 8.36/9.75 0.21
M/F (116/9) 23.7/23.4 0.93 2.66/3.32 0.04∗ 9.69/7.90 0.22
∗𝑝 < 0.05; ∗∗𝑝 < 0.01. Cat: cathepsin; Cys: cystatin; BMI: bodymass index; Cr: creatinine; VC: vital capacity; FEV1/FVC: ratio of forced expiratory volume in
1 second to forced vital capacity; FEV1: forced expiratory volume in 1 second; PEF: peak expiratory flow rate;𝑉50: the air flow rate at 50% vital capacity;DLCO:
diffusing capacity of the lung for carbon monoxide; DLCO/𝑉𝐴: diffusing capacity of the lung for carbon monoxide divided by the alveolar volume; LAA: low
attenuation area; mPA: main pulmonary artery; abAo: abdominal aorta; Ex: ex-smoker; HT: hypertension; ICS: inhaled corticosteroid;M: male; F: female.
Table 3: Logistic regression analysis for severe airflow limitation (% FEV1 predicted < 50).
Cathepsin S and % FEV1
predicted < 50
Cat S/Cys C (/103) and % FEV1
predicted < 50
𝜒2 𝑝 OR 95% CI 𝜒2 𝑝 OR 95% CI
Cat S (10 increments) 7.82 0.005∗∗ 0.32 0.14–0.71 — — — —
Cat S/Cys C (/103) — — — — 5.19 0.02∗ 0.87 0.77–0.98
Age (10 increments) 12.14 0.001∗∗ 3.82 1.80–8.12 10.76 0.001∗∗ 3.02 1.56–5.84
BMI 2.28 0.13 0.90 0.79–1.03 2.77 0.10 0.89 0.77–1.02
PY (10 increments) 2.46 0.12 1.11 0.97–1.27 1.21 0.27 1.07 0.95–1.22
Serum Cr 5.05 0.02∗ 0.02 0.001–0.60 6.35 0.01∗ 0.014 0.0005–0.39
Male 3.35 0.07 11.93 0.84–169.5 4.10 0.04∗ 15.13 1.09–209.5
Ex-smoker 1.44 0.23 1.88 0.67–5.28 2.97 0.09 2.45 0.88–6.79
HT (−) 2.18 0.14 0.40 0.12–1.35 2.09 0.15 0.42 0.13–1.36
ICS (−) 0.001 0.97 1.03 0.26–4.07 0.044 0.83 0.87 0.23–3.23
∗𝑝 < 0.05; ∗∗𝑝 < 0.01. FEV1: forced expiratory volume in 1 second; Cat: cathepsin; Cys: cystatin; OR: odds ratio; CI: confidence interval; BMI: body mass
index; PY: pack-years; Cr: creatinine; HT: hypertension; ICS: inhaled corticosteroid.
Taken together, we speculate that the inverse correlation
between plasma cathepsin S and cathepsin S/cystatin C ratios
and severity of airflow limitation and emphysema in patients
suggestive of COPD that we observed in this study might
reflect these complex processes in the pathophysiology of this
disease. However, additional cohorts of COPD and asthma
will be needed to confirm these findings. Symptomatic smok-
ers without pulmonary function decline are classified as Stage
0 disease and reported to have an increased susceptibility
to COPD in GOLD 2001. AR, that is Stage 0 disease,
develops COPD in 50% [29]. In addition, productive cough
is associated with hastening lung function decline for 5-
year follow-up when compared with COPD patients without
productive cough [30]. However, there is still little evidence
that cough is an important predictor of future progression in
Stage 0 patients. Plasma cathepsin S and cathepsin S/cystatin
C ratios may be clinically useful biomarkers to discriminate
susceptible individuals from nonsusceptible ones and asth-
matics prior to development of airflow limitation in COPD.
The mechanisms by which cathepsin S may contribute to
COPD pathogenesis are beyond the scope of the current
study. Although our study did not address any of these
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Table 4: Logistic regression analysis for significant emphysematous change (LAA ≥ 8.0).
Cathepsin S and LAA ≥ 8.0 Cat S/Cys C (/103) and LAA ≥ 8.0
𝜒2 𝑝 OR 95% CI 𝜒2 𝑝 OR 95% CI
Cat S (10 increments) 12.21 0.001∗∗ 0.28 0.14–0.57 — — — —
Cat S/Cys C (/103) — — — — 9.83 0.002∗∗ 0.82 0.72–0.93
Age (10 increments) 5.72 0.02∗ 2.08 1.14–3.78 3.76 0.052 1.72 0.99–2.98
BMI 3.45 0.06 0.87 0.75–1.01 4.36 0.04∗ 0.85 0.73–0.99
PY (10 increments) 1.92 0.17 1.09 0.96–1.24 0.74 0.39 1.05 0.94–1.19
Serum Cr 0.37 0.54 0.40 0.02–7.71 1.55 0.21 0.16 0.009–2.88
Male 1.28 0.26 3.17 0.43–23.4 2.51 0.11 4.71 0.69–32.1
Ex-smoker 0.31 0.58 1.30 0.51–3.29 1.46 0.23 1.76 0.70–4.42
HT (−) 0.84 0.36 0.58 0.18–1.86 0.77 0.38 0.60 0.20–1.87
ICS (−) 0.07 0.79 0.85 0.25–2.89 0.21 0.65 0.76 0.23–2.51
∗𝑝 < 0.05; ∗∗𝑝 < 0.01. LAA: low attenuation area; Cat: cathepsin; Cys: cystatin; OR: odds ratio; CI: confidence interval; BMI: body mass index; PY: pack-
years; Cr: creatinine; HT: hypertension; ICS: inhaled corticosteroid.
potential mechanisms, the observation that these biomarkers
are elevated in patients with COPD, especially in early stages,
comparedwith healthy smokers and nonsmokers should help
us direct more efforts in this area.
There are several limitations in our study. First, it was
impossible to obtain pulmonary function data from subjects
in the NS and HS groups. The healthy volunteers (NS and
HS) were differentiated from the patients (COPD and AR)
since they had no chronic respiratory symptoms leading to
visiting hospitals. Second, the mean age of the COPD group
was significantly higher than AR and the healthy subjects.
However, our results indicate that cathepsin S levels are not
affected by age (Table 2). Third, it is not clear which subjects
within the AR group will subsequently develop COPD and
whether plasma cathepsin S levels and cathepsin S/cystatin
C ratios will predict this progression. Longitudinal studies of
the AR group would be required to answer these questions. It
is also uncertain to what extent the plasma levels of cathepsin
S and cystatin C reflect the expression of these proteins in the
lung versus other origins such as adipose tissue.
5. Conclusion
We have demonstrated significantly elevated plasma levels of
cathepsin S and cystatin C, and plasma cathepsin S/cystatin C
ratios, in COPD patients versus healthy subjects. Our results
suggest that plasma cathepsin S concentrations and cathepsin
S/cystatin C ratios may serve as potential biomarkers for
COPD.
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